Advertisement
News
Subscribe to MDT Magazine News

Halozyme Therapeutics and ViroPharma Announce $83 Million Global Licensing Agreement to Develop Subcutaneous Cinryze® (C1 esterase inhibitor human)

May 11, 2011 5:34 am | by Bio-Medicine.Org | Comments

SAN DIEGO, May 11, 2011 /- Halozyme Therapeutics, Inc. (Nasdaq: HALO ) and ViroPharma Incorporated (Nasdaq: VPHM ), today announced the signing of a worldwide exclusive licensing agreement for the use of rHuPH20 (recombinant human hyaluronidase) in the development of a subcutaneous...

TOPICS:

Medco Research Institute® and AssureRx Health Initiate Pilot Program to Evaluate Adoption and Clinical Impact of Pharmacogenetic Testing for Selection of Psychotropic Medicat...

May 11, 2011 5:33 am | by Bio-Medicine.Org | Comments

FRANKLIN LAKES, N.J. and CINCINNATI, May 11, 2011 /- Medco Research Institute LLC , a wholly owned subsidiary of Medco Health Solutions Inc. (NYSE: MHS ), and AssureRx Health Inc. today announced the initiation of the PREDICT PSYMEDS pilot [Pharmacogenetic-Directed Prescribing of...

TOPICS:

Quest Diagnostics Announces Completion of Final Extension of the Subsequent Offering Period and Intent to Exercise Top-Up Option and Complete Merger

May 11, 2011 5:33 am | by Bio-Medicine.Org | Comments

MADISON, N.J., May 11, 2011 /- Quest Diagnostics Incorporated (NYSE: DGX ), the world's leading provider of diagnostic testing, information and services, and Spark Acquisition Corporation, its wholly owned subsidiary ("Spark"), announced today the completion of the final extension of the...

TOPICS:
Advertisement

Varian Medical Systems to Exhibit Full Spectrum of Prostate Cancer Treatment Approaches at the American Urological Association Meeting in Washington, D.C.

May 11, 2011 5:33 am | by Bio-Medicine.Org | Comments

PALO ALTO, Calif., May 11, 2011 /- Varian Medical Systems (NYSE: VAR ) will showcase the company's full spectrum of prostate cancer treatment technologies at the upcoming American Urological Association (AUA) Meeting in Washington, D.C.  During the meeting, Varian will sponsor a...

TOPICS:

2nd Asia-Pacific Osteoporosis & Bone Meeting -Submit your abstract by May 17th

May 11, 2011 5:33 am | by International Osteoporosis Foundation | Comments

Less than one week to abstract deadline - young Investigators eligible for awards

TOPICS:

Slim Xtreme Herbal Slimming Capsule: Undeclared Drug Ingredient

May 11, 2011 5:30 am | by U.S. Food & Drug Administration | Comments

Product marketed as a dietary supplement contains sibutramine, which may present a significant risk for patients with a history of coronary artery disease, congestive heart failure, arrhythmias or stroke.

TOPICS:

Medtronic says Canada clears heart device

May 11, 2011 4:45 am | by The Associated Press | Comments

Medtronic Inc. said Wednesday that Canadian regulators approved its Arctic Front cardiac cryoablation catheter system, which treats abnormal heart rhythms using extreme cold.The world's largest medical device maker said the Arctic Front system treats a type of irregular heartbeat called atrial...

Defibtech Lifeline and ReviveR Automated External Defibrillators (AEDs): Recall - Software Defect May Cancel Shock

May 11, 2011 4:34 am | by U.S. Food & Drug Administration | Comments

Defect may result in failure to resuscitate the patient.

Advertisement

Monotype Imaging to replace Dionex in S & P SmallCap

May 11, 2011 3:45 am | by The Associated Press | Comments

Standard & Poor's said Monotype Imaging Holdings Inc. will replace Dionex Corp. in the S&P SmallCap 600 index after the close of trading Friday.Dionex is being acquired by Thermo Fisher Scientific Inc., which is in the S&P 500. The deal is expected to be completed soon.Monotype Imaging...

Pacira Pharmaceuticals, Inc. Reports First Quarter 2011 Financial Results

May 11, 2011 3:34 am | by Bio-Medicine.Org | Comments

PARSIPPANY, N.J., May 11, 2011 /- Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX ), an emerging specialty pharmaceutical company, today announced financial results for the first quarter ended March 31, 2011, provided an update on the execution of its pre-commercial and launch strategies for...

TOPICS:

Dermatologist Using Robot for Dermatologic Emergencies

May 11, 2011 3:34 am | by Bio-Medicine.Org | Comments

DELRAY BEACH, Fla., May 11, 2011 /- Dermatology patients in Palm Beach County now have the comfort of knowing their doctor is available to see them for emergencies even when he is on vacation. Dr. Steven Hacker, a top selling author for physicians, and recognized by his peers as one of...

TOPICS:

Tourette Syndrome Association and Psyadon Pharmaceuticals to Collaborate on a Drug Trial for Tourette Syndrome Treatment

May 11, 2011 3:34 am | by Bio-Medicine.Org | Comments

BAYSIDE, N.Y. and GERMANTOWN, Md., May 11, 2011 /PRNewswire-USNewswire/ -- The national Tourette Syndrome Association (TSA) and Psyadon Pharmaceuticals Inc. are pleased to announce their collaboration on a clinical trial to determine the potential efficacy of a novel drug, ecopipam, for...

TOPICS:

Henry Schein Ranks #317 in 2011 Fortune 500 Ranking of America's Largest Corporations

May 11, 2011 3:33 am | by Bio-Medicine.Org | Comments

MELVILLE, N.Y., May 11, 2011 /- Henry Schein, Inc. (NASDAQ: HSIC ), the largest provider of health care products and services to office-based dental, medical and veterinary practitioners, has been ranked number 317 in the 2011 Fortune 500 ranking of America's Largest Corporations....

TOPICS:

Reportlinker Adds Orthopedic Devices Market in the Emerging Countries (China, India, Brazil) - Presenting New Avenues for Growth and Profitability

May 11, 2011 2:34 am | by Bio-Medicine.Org | Comments

NEW YORK, May 11, 2011 /- Reportlinker.com announces that a new market research report is available in its catalogue: Orthopedic Devices Market in the Emerging Countries (China, India, Brazil) - Presenting New Avenues for Growth and Profitability...

TOPICS:

Vemurafenib New Drug Application Submitted to FDA for Melanoma

May 11, 2011 2:31 am | by Bio-Medicine.Org | Comments

PARSIPPANY, N.J. and TOKYO, May 11, 2011 /- Daiichi Sankyo announced that applications have been submitted for market approval for vemurafenib (PLX4032/RG7204) for the treatment of metastatic melanoma to the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA)....

TOPICS:

Pages

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading